Overview

A global investment fund structured a USD 100 million financing package for a rapidly growing pharmaceutical manufacturing company in Africa. The objective was to provide long-term capital while aligning the interests of both the lender and the borrower through a combination of debt, equity participation, and performance-based returns.

Transaction Structure

Total Investment: USD 100 Million

Debt Component (USD 60M)

• Long-term capital for business expansion
• Manufacturing capacity enhancement
• Support for regulatory approvals
• International market expansion

Equity Component (USD 40M)

• Based on Enterprise Value valuation
• Investor positioned as strategic partner

Key Features

Buyback Option

• Available after 5 years
• Promoters may repurchase equity stake
• Defined exit mechanism for investor

Minimum Investor Return

• Guaranteed minimum return of 18% per annum
• Provides strong downside protection

Profit Sharing Above Hurdle Rate

• Returns above 18% shared equally
• Example:
  • 24% return → 3% investor + 3% borrower
  • 36% return → excess equally shared
• Encourages alignment and value creation

IPO Rights

• Participation in IPO process
• Liquidity upon listing
• Exit at market valuation

Benefits to Borrower

• Access to substantial long-term capital
• Lower dilution compared to traditional private equity
• Flexible buyback structure
• Strategic financial partnership
• Improved governance and credibility
• Shared upside without excessive liability

Benefits to Investor

• Diversified returns (debt + equity)
• Minimum 18% annual return protection
• Additional upside through profit-sharing
• Equity value appreciation
• Multiple exit options (IPO / buyback)
• Strong risk-adjusted returns

Conclusion

This hybrid financing structure combines debt, enterprise-value based equity, buyback rights, minimum return protection, performance-based profit sharing, and IPO exit rights into a unified investment framework. It creates a balanced partnership where both the borrower and investor benefit from long-term value creation while effectively managing downside risk.

Such structures are particularly suitable for high-growth sectors including pharmaceuticals, healthcare, manufacturing, renewable energy, infrastructure, and technology in emerging markets.